The kit is used to detect the neutralizing antibody to SARS-CoV-2 in human serum, plasma or whole blood sample quantitatively.
It is mainly used to identify individuals with acquired immune response to the SARS-CoV-2, and to evaluate the effectiveness of
the vaccine clinical trials and mass vaccination.
Sample types: whole blood, plasma, serum
Reaction Time: 15 mins
Results: quantitative
NAbs were detected from day 4 to day 6 after symptom onset and
peaked at day 10 to day 15
NAbs can be found in persons who have recovered from COVID-19
NAbs could help determine the optimal design and dosing of
vaccines
NAbs could help determine whether people needs the first
vaccination and the necessity and time point of Second vaccination
ANALYZER PARAMETERS
| Product name | Fluorescence Immunoassay Analyzer |
| Model | DIXION-DP-110, DIXION-DP-112, DIXION-DP-113 |
| Methodology | Time-resolved fluorescence immunoassay (TRFIA) |
| Test mode | Automatic mode, Manual mode, Following mode, Continuous mode |
| Storage | Up to 40000 test results |
| Communication | Connecting to LIS by COM or USB etc. |
| Printing
|
Built-in thermal printer, external printer optional
|
| Port
|
Serial Port, USB, Bluetooth (Wireless module),
Ethernet
|
| Detection speed
|
Under continuous mode, up to 200 tests/hour |
| Sample type
|
Whole blood, serum, plasma or body fluids
|
| Size
|
230mm*170mm*305mm
|
| Weight
|
About 2.4kg
|
